camostat has been researched along with Nephrosis, Lipoid in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Nephrosis, Lipoid: A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsubara, M | 1 |
| Nogae, S | 1 |
| Ito, S | 1 |
1 other study available for camostat and Nephrosis, Lipoid
| Article | Year |
|---|---|
Novel trial for the treatment of steroid dependency in minimal change disease: combined therapy of camostat mesilate and glycyrrhizin.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Th | 2002 |